[ad_1]
Key news from the Proactive Investors UK press room.
Redx Pharma (LON: REDX) has agreed to sell its treatment for mutant tumors to the US group Jazz Pharmaceuticals for US $ 3.5 million, to which an additional US $ 203 million is added. Jazz will be responsible for all future development, regulatory, manufacturing and marketing activities.
Simec Atlantis (LON: SAE) reports that its MeyGen project off the Scottish coast has managed the longest period of uninterrupted power generation ever seen from a tsunami project. MeyGen generated revenues of £ 1.85 million this year.
The Bango mobile commerce group (LON: BGO) became profitable in the second quarter of 2019, while user spending on its platform increased again. Revenues during the half year increased by 64% to £ 4.3m.
Feedback PLC (LON: FDBK) reports that its Dial system has priority over its TexRAD technology for biomarker discovery in medical images. This shift in tactics follows a strategic badysis of new CEO Tom Oakley, who believes that Cadran can become the method of securely sharing patient information by mobile phone or tablet.
Barratt's profits this year will exceed expectations at around 910 million pounds, after a strong year-end and better margins. Forward sales for 2020 are 20% higher at £ 2.6 billion.
Source link
